Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200462918> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W4200462918 endingPage "S48" @default.
- W4200462918 startingPage "S48" @default.
- W4200462918 abstract "Abstract Background Lenacapavir (LEN) is a first-in-class HIV-1 capsid (CA) inhibitor in clinical development for treatment and prevention of HIV-1 infection. CALIBRATE is an ongoing, phase 2 clinical study evaluating subcutaneous (SC) or oral LEN, in combination with other antiretrovirals, in treatment-naïve people with HIV-1. High rates of virologic success (HIV-1 RNA < 50 copies/mL) were achieved with LEN-based regimens by FDA Snapshot analysis at Week 28. Here, we present interim resistance analyses through Week 28. Methods Participants were randomized (2:2:2:1) to treatment groups (TG) (Figure): SC LEN + oral daily emtricitabine/tenofovir alafenamide (F/TAF); at Week 28, participants switch F/TAF to oral TAF (TG-A) or bictegravir (B, BIC) (TG-B); oral daily LEN + F/TAF (TG-C), or oral daily B/F/TAF (TG-D). Genotypic analyses (population sequencing) of HIV-1 reverse transcriptase and integrase, and genotypic (deep sequencing)/phenotypic analyses for CA were performed at screening; genotypic and phenotypic analyses were conducted at confirmed virologic failure. Figure CALIBRATE Study Design Results 182 participants were randomized and dosed in TG-A to D (n=52, 53, 52, 25). Most participants had subtype B HIV-1 (92.9%). Sequence analysis of baseline samples found 65% of amino acid residues were conserved with < 1% variation across CA overall, and 55% of residues were fully conserved. No mutations were detected at 6 positions in CA associated with reduced susceptibility to LEN in vitro; residues were fully conserved at 5 positions (L56, M66, Q67, K70, N74), and < 2% variation was observed at 1 position (T107). Three participants met the criteria for resistance analysis: 2 participants resuppressed to < 50 copies/mL while continuing treatment. One participant on SC LEN + F/TAF developed emergent resistance to LEN (Q67H+K70R) and emtricitabine (M184M/I), followed by resuppression after starting dolutegravir, zidovudine + lamivudine, tenofovir disoproxil fumarate. Conclusion Emergent resistance to LEN was uncommon in treatment-naïve participants receiving SC or oral LEN (0.6%, 1/157). These interim resistance findings support the ongoing evaluation of LEN for treatment and prevention of HIV. Disclosures Laurie VanderVeen, PhD, Gilead Sciences (Employee, Shareholder) Nicolas Margot, MA, Gilead Sciences (Employee, Shareholder) Vidula Naik, MSc, Gilead Sciences (Employee, Shareholder) Silvia Chang, Masters, Gilead Sciences, Inc (Employee, Shareholder) Ross Martin, PhD, Gilead Sciences, Inc (Employee, Shareholder) Hadas Dvory-Sobol, PhD, Gilead Sciences (Employee, Shareholder) Martin Rhee, MD, Gilead Sciences (Employee, Shareholder) Christian Callebaut, PhD, Gilead Sciences (Employee, Shareholder)" @default.
- W4200462918 created "2021-12-31" @default.
- W4200462918 creator A5007563271 @default.
- W4200462918 creator A5027618515 @default.
- W4200462918 creator A5040302698 @default.
- W4200462918 creator A5050260467 @default.
- W4200462918 creator A5051466983 @default.
- W4200462918 creator A5063608706 @default.
- W4200462918 creator A5085171999 @default.
- W4200462918 creator A5087385117 @default.
- W4200462918 date "2021-11-01" @default.
- W4200462918 modified "2023-09-27" @default.
- W4200462918 title "73. Interim Resistance Analysis of Long-Acting Lenacapavir in Treatment-Naïve People with HIV at 28 Weeks" @default.
- W4200462918 doi "https://doi.org/10.1093/ofid/ofab466.073" @default.
- W4200462918 hasPublicationYear "2021" @default.
- W4200462918 type Work @default.
- W4200462918 citedByCount "3" @default.
- W4200462918 countsByYear W42004629182022 @default.
- W4200462918 countsByYear W42004629182023 @default.
- W4200462918 crossrefType "journal-article" @default.
- W4200462918 hasAuthorship W4200462918A5007563271 @default.
- W4200462918 hasAuthorship W4200462918A5027618515 @default.
- W4200462918 hasAuthorship W4200462918A5040302698 @default.
- W4200462918 hasAuthorship W4200462918A5050260467 @default.
- W4200462918 hasAuthorship W4200462918A5051466983 @default.
- W4200462918 hasAuthorship W4200462918A5063608706 @default.
- W4200462918 hasAuthorship W4200462918A5085171999 @default.
- W4200462918 hasAuthorship W4200462918A5087385117 @default.
- W4200462918 hasBestOaLocation W42004629181 @default.
- W4200462918 hasConcept C104317684 @default.
- W4200462918 hasConcept C126322002 @default.
- W4200462918 hasConcept C135763542 @default.
- W4200462918 hasConcept C142462285 @default.
- W4200462918 hasConcept C159047783 @default.
- W4200462918 hasConcept C2778451633 @default.
- W4200462918 hasConcept C2779778239 @default.
- W4200462918 hasConcept C2908647359 @default.
- W4200462918 hasConcept C2911190787 @default.
- W4200462918 hasConcept C2993143319 @default.
- W4200462918 hasConcept C3013748606 @default.
- W4200462918 hasConcept C54355233 @default.
- W4200462918 hasConcept C71924100 @default.
- W4200462918 hasConcept C86803240 @default.
- W4200462918 hasConcept C90924648 @default.
- W4200462918 hasConcept C99454951 @default.
- W4200462918 hasConceptScore W4200462918C104317684 @default.
- W4200462918 hasConceptScore W4200462918C126322002 @default.
- W4200462918 hasConceptScore W4200462918C135763542 @default.
- W4200462918 hasConceptScore W4200462918C142462285 @default.
- W4200462918 hasConceptScore W4200462918C159047783 @default.
- W4200462918 hasConceptScore W4200462918C2778451633 @default.
- W4200462918 hasConceptScore W4200462918C2779778239 @default.
- W4200462918 hasConceptScore W4200462918C2908647359 @default.
- W4200462918 hasConceptScore W4200462918C2911190787 @default.
- W4200462918 hasConceptScore W4200462918C2993143319 @default.
- W4200462918 hasConceptScore W4200462918C3013748606 @default.
- W4200462918 hasConceptScore W4200462918C54355233 @default.
- W4200462918 hasConceptScore W4200462918C71924100 @default.
- W4200462918 hasConceptScore W4200462918C86803240 @default.
- W4200462918 hasConceptScore W4200462918C90924648 @default.
- W4200462918 hasConceptScore W4200462918C99454951 @default.
- W4200462918 hasIssue "Supplement_1" @default.
- W4200462918 hasLocation W42004629181 @default.
- W4200462918 hasLocation W42004629182 @default.
- W4200462918 hasOpenAccess W4200462918 @default.
- W4200462918 hasPrimaryLocation W42004629181 @default.
- W4200462918 hasRelatedWork W2586080517 @default.
- W4200462918 hasRelatedWork W2802509574 @default.
- W4200462918 hasRelatedWork W2895201968 @default.
- W4200462918 hasRelatedWork W2995517530 @default.
- W4200462918 hasRelatedWork W3071193106 @default.
- W4200462918 hasRelatedWork W4200201718 @default.
- W4200462918 hasRelatedWork W4229000754 @default.
- W4200462918 hasRelatedWork W4247340174 @default.
- W4200462918 hasRelatedWork W4293507321 @default.
- W4200462918 hasRelatedWork W4361005624 @default.
- W4200462918 hasVolume "8" @default.
- W4200462918 isParatext "false" @default.
- W4200462918 isRetracted "false" @default.
- W4200462918 workType "article" @default.